Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Czech Republic: Locatop; Finland: Apolar; France: Cirkan, Desonide, Desowen, Locapred, Locatop, Tridenosit; Greece: Sterax; Italy: Prenacid, Reticus, Sterades; Luxembourg: Sterax; Poland: Locatop; Portugal: Locapred, Zotinar; Romania: Prenacid.

North America

Canada: Desocort, Desonide; USA: Desonate, Desonide, Desowen, Verdeso.

Latin America

Argentina: Desoplus, Locatop; Brazil: Desonida, Desonol; Mexico: Dersupril, Desowen.

Drug combinations


Desonide: C~24~H~32~O~6~. Mw: 416.51. (1) Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11β,16α)-; (2) 11β,16α,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone. CAS-638-94-8 (1970).

Pharmacologic Category

Skin and Mucous Membrane Agents; Anti-inflammatory Agents. Topical Corticosteroid. (ATC-Code: D07AB08; S01BA11).

Mechanism of action

A synthetic corticosteroid. Stimulates the synthesis of enzymes needed to decrease inflammation, suppress mitotic activity, and cause vasoconstriction.

Therapeutic use

Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g. seborrheic or atopic dermatitis, localized neurodermatitis, anogenital pruritus, psoriasis, late phase of allergic contact dermatitis, inflammatory phase of xerosis).

Pregnancy and lactiation implications

Teratogenic events not observed in animals following topical administration. Teratogenic events reported following systemic use of corticosteroids. Use with caution while breast-feeding.

Unlabeled use


Hypersensitivity to desonide or any component of the formulation.

Warnings and precautions

Allergic contact dermatitis can occur (may manifest as failure to heal). Development of Kaposi’s sarcoma with prolonged treatment (case reports) with corticosteroids. Adverse systemic effects including Cushing’s syndrome, hyperglycemia, glycosuria, fluid and electrolyte changes, and reversible HPA axis suppression (particularly in younger children) may occur when used on large surface areas, for prolonged periods, or with an occlusive dressing and/or concurrently with other corticosteroid-containing preparations. Chronic use of corticosteroids in children may interfere with growth and development. Children are at greater risk of glucocorticoid insufficiency during and/or after withdrawal of treatment. Intracranial hypertension has occurred in children. Striae reported in children treated inappropriately with topical corticosteroids. For dermatologic use only. Not for oral or intravaginal use. Prolonged use of topical corticosteroids may cause atrophy of the epidermis and subcutaneous tissue mostly in intertriginous (e.g. axilla, groin), flexor, and facial areas. Avoid using occlusive dressings on weeping or exudative lesions.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart